In addition, P300 is also a co-activator BRCA1 [33], and it mediates histone acetylation at the sites of double strand DNA breaks [34] thus facilitating DNA repair; its inhibition might therefore constitute another interesting strategy to sensitize ovarian cancer to the action of PARP inhibitors. Here, BRCA1 is linked to ovarian cancer.